OpenAI CEO Sam Altman backs Retro Biosciences, a San Francisco-based biotech startup that wishes people to live 10 years longer than what it calls a healthy human lifespan.
Altman before provided Retro Biosciences' total seed round is $180 million. Now the startup is raising $1 billion in Series A funding, which Altman is joining. the Financial Times Reports.
Retro Biosciences, which says it wants to start out trials for drugs against diseases akin to Alzheimer's, recently trained a model with OpenAI to convert normal cells into stem cells.
CEO Joe Betts-LaCroix told the FT he desired to move quickly and discover and develop a drug “within the 2020s”.
The startup joins other major billionaire-backed longevity efforts, including Altos Labs began with $3 billion in 2022, backed by Jeff Bezos and Unity Biotechnology, supports by Bezos and Peter Thiel.
